FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase - FGFR4 complex

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 36, 2010, Pages 15786-15791

  Sugiyama, Nami ^a,b   Varjosalo, Markku ^b   Meller, Pipsa ^a,b   Lohi, Jouko ^a   Chan, Kui Ming ^c   Zhou, Zhongjun ^c   Alitalo, Kari ^a   Taipale, Jussi ^b,d   Keski Oja, Jorma ^a   Lehti, Kaisa ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ECM; Invasion; MMP14; Proteolysis; Signaling

Indexed keywords

COLLAGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; MATRIX METALLOPROTEINASE 14; FGFR4 PROTEIN, HUMAN;

ALLELE; ARTICLE; AUTOPHOSPHORYLATION; CANCER INVASION; CELL JUNCTION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ENDOSOME; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR CELL; TUMOR GROWTH; ENZYME STABILITY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ENDOSOMES; ENZYME STABILITY; HUMANS; LYSOSOMES; MATRIX METALLOPROTEINASE 14; PHOSPHORYLATION; POLYMORPHISM, GENETIC; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; SIGNAL TRANSDUCTION;

EID: 77957686550     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914459107     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
2. Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28:15-33.
3. Rowe RG, Weiss SJ (2009) Navigating ECM barriers at the invasive front: The cancer cell-stroma interface. Annu Rev Cell Dev Biol 25:567-595.
4. Friedl P, Wolf K (2010) Plasticity of cell migration: A multiscale tuning model. J Cell Biol 188:11-19.
5. Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7:737-749.
6. Tsunezuka Y, et al. (1996) Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res 56:5678-5683. (Pubitemid 26422172)
7. Devy L, et al. (2009) Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69:1517-1526.
8. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221-233.
9. Kinoh H, et al. (1996) MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 109:953-959. (Pubitemid 26168248)
10. Lohi J, Lehti K, Westermarck J, Kähäri VM, Keski-Oja J (1996) Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. Eur J Biochem 239:239-247.
11. Apte SS, Fukai N, Beier DR, Olsen BR (1997) The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. J Biol Chem 272:25511-25517.
12. Rajavashisth TB, et al. (1999) Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 274:11924-11929.
13. Ota K, et al. (1998) Cloning of murine membrane-type-1-matrix metalloproteinase (MT-1-MMP) and its metanephric developmental regulation with respect to MMP-2 and its inhibitor. Kidney Int 54:131-142. (Pubitemid 28288027)
14. Blavier L, et al. (2001) TGF-beta3-induced palatogenesis requires matrix metalloproteinases. Mol Biol Cell 12:1457-1466.
15. Lehti K, Valtanen H, Wickström SA, Lohi J, Keski-Oja J (2000) Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. J Biol Chem 275:15006-15013.
16. Maquoi E, et al. (2000) Membrane type 1 matrix metalloproteinase- associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell lines. J Biol Chem 275:11368-11378.
17. Jiang A, et al. (2001) Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci USA 98:13693-13698. (Pubitemid 33115960)
18. Uekita T, Itoh Y, Yana I, Ohno H, Seiki M (2001) Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 155:1345-1356.
19. Zucker S, Hymowitz M, Conner CE, DiYanni EA, Cao J (2002) Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase a activation. Lab Invest 82:1673-1684.
20. Overall CM, Kleifeld O (2006) Tumour microenvironment - opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6:227-239.
21. Zhou Z, et al. (2000) Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 97:4052-4057.
22. Holmbeck K, Bianco P, Yamada S, Birkedal-Hansen H (2004) MT1-MMP: A tethered collagenase. J Cell Physiol 200:11-19.
23. Bange J, et al. (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62:840-847.
24. Streit S, et al. (2004) Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer 111:213-217. (Pubitemid 38924697)
25. Stadler CR, Knyazev P, Bange J, Ullrich A (2006) FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cell Signal 18:783-794.
26. Ho HK, et al. (2009) Fibroblast growth factor receptor 4 regulates proliferation, antiapoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50:118-127.
27. Seitzer N, Mayr T, Streit S, Ullrich A (2010) A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 70:802-812.
28. Wang J, Yu W, Cai Y, Ren C, Ittmann MM (2008) Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia 10:847-856.
29. Varjosalo M, et al. (2008) Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling. Cell 133:537-548.
30. Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M (2003) Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: Importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 22:8716-8722.
31. Munshi HG, et al. (2004) Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis. J Biol Chem 279:39042-39050.
32. Nyalendo C, et al. (2007) Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: Role in endothelial and tumor cell migration. J Biol Chem 282:15690-15699.
33. Nyalendo C, et al. (2008) Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis 29:1655-1664.
34. Moss NM, et al. (2009) Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res 7:809-820.
35. Hotary K, Allen E, Punturieri A, Yana I, Weiss SJ (2000) Regulation of cell invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J Cell Biol 149:1309-1323.
36. Cao J, et al. (2008) Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer. J Biol Chem 283:6232-6240.
37. Sabeh F, Shimizu-Hirota R, Weiss SJ (2009) Protease-dependent versus -independent cancer cell invasion programs: Three-dimensional amoeboid movement revisited. J Cell Biol 185:11-19.
38. Spinola M, et al. (2005) Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol 23:7307-7311.
39. da Costa Andrade VC, et al. (2007) The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 82:53-57.
40. Sahadevan K, et al. (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 213:82-90. (Pubitemid 47354569)
41. Cho JY, et al. (2004) Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 101:609-614.
42. Eswarakumar VP, Lax I, Schlessinger J (2005) Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16:139-149.
43. White KE, et al. (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361-367.
44. Pulleyn LJ, et al. (1996) Spectrum of craniosynostosis phenotypes associated with novel mutations at the fibroblast growth factor receptor 2 locus. Eur J Hum Genet 4:283-291.
45. Gálvez BG, Matías-Román S, Yáñez- Mó M, Sánchez-Madrid F, Arroyo AG (2002) ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 159:509-521.
46. Nakamura T, et al. (2008) PX-RICS mediates ER-to-Golgi transport of the N-cadherin/beta-catenin complex. Genes Dev 22:1244-1256. (Pubitemid 351656582)
47. Jaakkola S, et al. (1993) Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 54:378-382.